446 related articles for article (PubMed ID: 23911321)
1. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.
Chan CH; Morrow JK; Li CF; Gao Y; Jin G; Moten A; Stagg LJ; Ladbury JE; Cai Z; Xu D; Logothetis CJ; Hung MC; Zhang S; Lin HK
Cell; 2013 Aug; 154(3):556-68. PubMed ID: 23911321
[TBL] [Abstract][Full Text] [Related]
2. Virtual drug design: Skp1-Skp2 inhibition targets cancer stem cells.
Pascal LE; Wang Z
Asian J Androl; 2013 Nov; 15(6):717-8. PubMed ID: 24077600
[TBL] [Abstract][Full Text] [Related]
3. Skp2: a dream target in the coming age of cancer therapy.
Chan CH; Morrow JK; Zhang S; Lin HK
Cell Cycle; 2014; 13(5):679-80. PubMed ID: 24526126
[No Abstract] [Full Text] [Related]
4. Pharmacogenomics and chemical library screens reveal a novel SCF
Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
[TBL] [Abstract][Full Text] [Related]
5. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
Chen Q; Xie W; Kuhn DJ; Voorhees PM; Lopez-Girona A; Mendy D; Corral LG; Krenitsky VP; Xu W; Moutouh-de Parseval L; Webb DR; Mercurio F; Nakayama KI; Nakayama K; Orlowski RZ
Blood; 2008 May; 111(9):4690-9. PubMed ID: 18305219
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1.
Ungermannova D; Lee J; Zhang G; Dallmann HG; McHenry CS; Liu X
J Biomol Screen; 2013 Sep; 18(8):910-20. PubMed ID: 23589337
[TBL] [Abstract][Full Text] [Related]
7. Specific small molecule inhibitors of Skp2-mediated p27 degradation.
Wu L; Grigoryan AV; Li Y; Hao B; Pagano M; Cardozo TJ
Chem Biol; 2012 Dec; 19(12):1515-24. PubMed ID: 23261596
[TBL] [Abstract][Full Text] [Related]
8. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
9. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
Masumoto K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Pavlides SC; Huang KT; Reid DA; Wu L; Blank SV; Mittal K; Guo L; Rothenberg E; Rueda B; Cardozo T; Gold LI
Endocrinology; 2013 Nov; 154(11):4030-45. PubMed ID: 24035998
[TBL] [Abstract][Full Text] [Related]
11. Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
He DH; Chen YF; Zhou YL; Zhang SB; Hong M; Yu X; Wei SF; Fan XZ; Li SY; Wang Q; Lu Y; Liu YQ
Cancer Sci; 2021 Aug; 112(8):3218-3232. PubMed ID: 34080260
[TBL] [Abstract][Full Text] [Related]
12. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.
Lin HK; Chen Z; Wang G; Nardella C; Lee SW; Chan CH; Yang WL; Wang J; Egia A; Nakayama KI; Cordon-Cardo C; Teruya-Feldstein J; Pandolfi PP
Nature; 2010 Mar; 464(7287):374-9. PubMed ID: 20237562
[TBL] [Abstract][Full Text] [Related]
13. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis.
Wang G; Chan CH; Gao Y; Lin HK
Chin J Cancer; 2012 Apr; 31(4):169-77. PubMed ID: 22200179
[TBL] [Abstract][Full Text] [Related]
14. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
Kitagawa K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
[TBL] [Abstract][Full Text] [Related]
15. Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor.
Cheng X; Liu YQ; Wang GZ; Yang LN; Lu YZ; Li XC; Zhou B; Qu LW; Wang XL; Cheng YX; Liu J; Tao SC; Zhou GB
Oncotarget; 2017 Jan; 8(2):2681-2693. PubMed ID: 27835873
[TBL] [Abstract][Full Text] [Related]
16. Skp2 Inhibitors: Novel Anticancer Strategies.
Lee Y; Lim HS
Curr Med Chem; 2016; 23(22):2363-79. PubMed ID: 27160538
[TBL] [Abstract][Full Text] [Related]
17. E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy.
Hao Z; Huang S
Front Biosci (Landmark Ed); 2015 Jan; 20(3):474-90. PubMed ID: 25553462
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase.
Hao B; Zheng N; Schulman BA; Wu G; Miller JJ; Pagano M; Pavletich NP
Mol Cell; 2005 Oct; 20(1):9-19. PubMed ID: 16209941
[TBL] [Abstract][Full Text] [Related]
19. E3-ligase Skp2 predicts poor prognosis and maintains cancer stem cell pool in nasopharyngeal carcinoma.
Wang J; Huang Y; Guan Z; Zhang JL; Su HK; Zhang W; Yue CF; Yan M; Guan S; Liu QQ
Oncotarget; 2014 Jul; 5(14):5591-601. PubMed ID: 25015320
[TBL] [Abstract][Full Text] [Related]
20. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis.
Chan CH; Li CF; Yang WL; Gao Y; Lee SW; Feng Z; Huang HY; Tsai KK; Flores LG; Shao Y; Hazle JD; Yu D; Wei W; Sarbassov D; Hung MC; Nakayama KI; Lin HK
Cell; 2012 May; 149(5):1098-111. PubMed ID: 22632973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
